DURECT's resubmitted NDA for POSIMIR is under FDA review - with a decision expected by December 27, 2019. DUR-928 in IV form showed positive results in a Phase 2a trial and additional data is expected at the upcoming AASLD Liver Meeting in Boston in November. Given the fact that the company has upcoming clinical trial and regulatory catalysts, this stock is worth keeping an eye on.
from RTT - Biotech https://ift.tt/34YUeFL
via IFTTT
No comments:
Post a Comment